IldefonsoIsmaelRodriguez RiveraMD
Oncology • San Antonio, TXHematologic Oncology
Clinical Investigator, NEXT Oncology / Texas Oncology
Dr. Rodriguez Rivera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2829 Babcock Rd
Ste 300
San Antonio, TX 78229Phone+1 210-580-9500Fax+1 210-568-4397
Summary
- Dr. Ildefonso Rodriguez Rivera is a Phase 1 clinical investigator, hematologist and medical oncologist in San Antonio, TX and is affiliated with multiple hospitals in the area. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 6 years. He also speaks multiple languages, including Spanish. He specializes in Phase 1 clinical trials and hematologic malignancies.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2018
University of Texas at Austin Dell Medical SchoolResidency, Internal Medicine, 2014 - 2015
University of Texas M D Anderson Cancer CenterResidency, Research, 2013 - 2014
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2011 - 2014
University of Texas Southwestern Medical SchoolClass of 2011
Certifications & Licensure
NY State Medical License 2015 - 2026
TX State Medical License 2014 - 2026
NC State Medical License 2020 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chief Fellow Weill Cornell Medicine / Division of Hematology and Medical Oncology, 2017-2018
- Betty Lee Neuwirth Foundation Fellow in Oncology 2017
Clinical Trials
- A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Start of enrollment: 2017 Dec 28
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Apr 03
- A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2020 Feb 07
Publications & Presentations
PubMed
- 86 citationsPhase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2021-06-25 - 67 citationsOutcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.David Sermer, Connie L Batlevi, M. Lia Palomba, Gunjan L. Shah, Richard J. Lin
Blood Advances. 2020-10-13 - 2 citationsClinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi
Blood Cancer Journal. 2022-02-10
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaIldefonso Rodriguez-Rivera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Ildefonso Rodriguez-Rivera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
Other Languages
- Spanish
External Links
- Texas Oncologyhttps://www.texasoncology.com/oncologist/ildefonso-rodriguez-rivera
- Next Oncology https://nextoncology.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
